-
Antibody Target
BRCA2
-
Accession
116508
-
Gene ID
675
-
Appearance
Colorless liquid
-
Concentration
0.5 mg/ml
-
Formulation
50 µg (0.5 mg/ml) in phosphate buffered saline (PBS), pH 7.2, containing 50% glycerol, 1% BSA and 0.02% thimerosal.
-
Application Usage
The peptide is used for blocking the antibody activity of BRCA2 (Cat.# 3675-100). It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30-60 minutes at 37°C.
-
Storage Temp
-20 °C
-
Shipping
gel pack
-
Shelf Life
12 months
-
Western Blot WB
Verified
-
Handling
The peptide solution should be gently mixed before use.
-
-
Research Use
For Rersearch Use Only! Not to be used in humans.
-
Test
You can block the antibody by the specific target amino acid sequence of peptide.
-
Properties
blocking peptide
-
Description
Peptides short amino acid chains or epitopes or blocking antagonists. The shortest peptides are dipeptides, consisting of 2 amino acids joined by a single peptide bond, followed by tripeptides, tetra peptides, ... till polypeptides that are long, continuous, and unbranched synthetic peptide chains. These biological oligomers and polymers can be Solid-phase peptide synthesis (SPPS), or in continue produced for custom peptide synthesis projects. The High-efficiency solid phase peptide synthesis (HE-SPPS) is give very low production costs.
-
Gene target
-
Gene symbol
BRCA2
-
Short name
BRCA2 Blocking Peptide
-
Technique
blocking peptide, Blocking, peptide, blocking peptides, Biovision made this blocking amino acid sequence or peptide to block the gene target in a volume of 1. For western blot it is often requested to block your antibody and to see the band of the analyzed protein disappear. This is called a negative control by blocking the WB antibody. peptides
-
Alternative name
breast cancer 2, early onset inhibiting short protein sequence
-
Alternative technique
control, peptides
-
Alternative to gene target
breast cancer 2, early onset, BRCC2 and BROVCA2 and FACD and FAD and FAD1 and FANCD and FANCD1 and GLM3 and PNCA2, BRCA2 and IDBG-22703 and ENSG00000139618 and 675, gamma-tubulin binding, nuclei, Brca2 and IDBG-209587 and ENSMUSG00000041147 and 12190, BRCA2 and IDBG-630223 and ENSBTAG00000000988 and
-